Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 33

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 33
---
5, respectively (“Section 16 Reporting”). Executive Officers, Directors and greater than 10% shareholders are required by Commission regulations to furnish the Company with copies of all Section 16(a) reports they file.

During this current fiscal year, the Section 16 Reporting was complied with by the Company’s Officers, Directors and greater than 10% shareholders. 

Item 11. Executive Compensation.

Summary Executive Compensation Table

The following table reflects the Summary Compensation for our named Executive Officers for fiscal years ended December 31, 2024 and 2023, respectively. For such periods, there were no bonus, non-equity plan compensation, nonqualified compensation earnings or other compensation other than as stated below for the named executive officers. Further, we have not entered into an employment agreement with any of our officers, directors or any other persons and no such agreements are anticipated in the immediate future.

Name and principal position Year Salary($)  Bonus($)  Stock Awards($)  Option Awards($)  Non-Equity IncentivePlanCompensation($)  Nonqualified DeferredCompensationEarnings($)  All Other Compensation($)  Total($) Yeat Min Fong 2024  —   —   —   —   —   —   —   — Former Chairman (1) 2023 $16,069  $—  $7,583  $—   —   —  $—  $23,652 Yee Meng Wong 2024  —   —   —   —   —   —   —   — Former President (2) 2023 $16,069  $—  $7,583  $—   —   —  $—  $23,652 Sook Keng Yeoh 2024  —   —   —   —   —   —   —   — Former Chief Executive Officer (3) 2023 $12,000  $—  $7,583  $—   —   —  $—  $19,583 Chi Yuen Leong  Former Chief  2024  —   —   —   —   —   —   —   — Executive  Officer (4